Anika Therapeutics (STU:AKP) ROCE % : -8.54% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Anika Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anika Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -8.54%.

Anika Therapeutics ROCE % Historical Data

The historical data trend for Anika Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics ROCE % Chart

Anika Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

11.89

-4.30

-5.93

-6.27

-8.93

Anika Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-15.81	-4.69	-10.22	-2.33	-8.54

Anika Therapeutics ROCE % Calculation

Anika Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-23.337	/	( ( (329.577 - 26.351)	+	(248.17 - 28.481) )	/ 2 )
	=	-23.337	/	( (303.226	+	219.689)	/ 2 )
	=	-23.337	/	261.4575
	=	-8.93 %

Anika Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-18.632	/	( ( (248.17 - 28.481)	+	(242.644 - 26.183) )	/ 2 )
	=	-18.632	/	( ( 219.689	+	216.461 )	/ 2 )
	=	-18.632	/	218.075
	=	-8.54 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Anika Therapeutics (STU:AKP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anika Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anika Therapeutics (STU:AKP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (STU:AKP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ANIK:USA AKP:Germany

Address

32 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.anika.com

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.